Jones Financial Companies
TPST icon

Jones Financial Companies’s Tempest Therapeutics TPST Stock Holding History

Jones Financial Companies’s Portfolio TPST Stock Details TPST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$413 Hold
239
– – ﹤0.01% 4520
2025
Q4 		$686 Buy
+239
New +$1.69K ﹤0.01% 4100

Other funds holding TPST

VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Jones Financial Companies's TPST Position: Q1 2026 in Review

Jones Financial Companies held its Tempest Therapeutics (TPST) position steady in Q1 2026 at 239 shares worth $413. The position accounts for ﹤0.01% of the portfolio, ranked #4520.

Jones Financial Companies first reported a position in TPST in Q4 2025 and has held it in 2 quarters since. The position peaked at $686 in Q4 2025. 22 funds tracked by Wall St. Rank hold TPST as of Q1 2026.

  • Jones Financial Companies held 239 shares of Tempest Therapeutics worth $413 as of Q1 2026.
  • Jones Financial Companies left its Tempest Therapeutics share count unchanged in Q1 2026.
  • Tempest Therapeutics made up ﹤0.01% of Jones Financial Companies's portfolio in Q1 2026, its #4520 holding.
  • Jones Financial Companies first reported a position in Tempest Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • Jones Financial Companies's Tempest Therapeutics position peaked at $686 in Q4 2025.
  • 22 funds tracked by Wall St. Rank held Tempest Therapeutics as of Q1 2026.

Based on Jones Financial Companies's 13F filing for Q1 2026, filed 15 May 2026.